	Application No.	Applicant(s)
	10/805,860	HALIEL ET AL
Notice of Allowability	Examiner	HAUEL ET AL. Art Unit
	Amelia A. Owens	1625
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.  1. This communication is responsive to amdt filed 4/21/2005.		
2. ☑ The allowed claim(s) is/are <u>3-6 and 8-13</u> .		
3. The drawings filed on are accepted by the Examiner.		
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a All b) Some* c) None of the:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
<ul> <li>6. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.</li> <li>(a) including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached</li> <li>1) hereto or 2) to Paper No./Mail Date</li> <li>(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date</li> <li>Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).</li> </ul>		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summary Paper No./Mail Da 8), 7. ☑ Examiner's Amend	te

Application/Control Number: 10/805,860

Art Unit: 1625

## Page 2

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.


Compounds of formula I where X = N; Y = S; R2 is as defined and A/R1 are nonheterocyclic was elected in response filed November 19, 2004. The search was expanded to include compounds where Y also is oxygen.

The application has been amended as follows:

Claim 8 line 8 delete 'derivative'

Replace claims 1,2,7 with the following:

----11. A compound of formula (1)



wherein the elements X, Y, A, R1, R2 and R3 have the following meanings:

X denotes a nitrogen atom (N);

Y denotes an oxygen atom or sulphur atom;

A denotes an unsubstituted or substituted phenyl;

R1 denotes hydroxy, fluorine, chlorine or bromine, amino, (C1-6)alkylamino, di(C1-6)alkylamino, (C3-7)cycloalkylamino, di(C3-7)cycloalkylamino, (C1-6)alkyl-(C3-7)cycloalkylamino, or acetidin-l-yl; and

R2 and R3 independently of one another denote hydrogen, (C1-8)alkyl or

Art Unit: 1625

(C3-7)cycloalkyl, or a salt thereof.

Claim 12. The compound of claim 11, wherein the group A is phenyl, unsubstituted or substituted by the groups R4, R5 and R6 where R4, R5 and R6 independently of one another denote hydrogen, (C1-8)alkyl, monofluoro(C1-5)alkyl, difluoro(C1-5)alkyl, trifluoro(C1-5)alkyl, (C3-7)cycloalkyl, hydroxy, (Cl-6)alkoxy, fluoromethyloxy, difluoromethyloxy, tifluoromethyloxy, (C3-6)cycloalkyloxy, fluorine, chlorine, bromine, carboxy, (C1-6)alkoxycarbonyl, amino, (Cl-6)alkylamino, di(C1-6)alkylamino, acetidin-l-yl, (Cl-4)acylamino, (Cl-6)alkyl-(C1-4)acylamino, aminocarbonyl, (Cl-6)alkylaminocarbonyl, di(C16)alkylaminocarbonyl, or acetidin-l-yl-carbonyl.

Claim 13. The compound of claim 11 selected from among the compounds:

9-dimethylamino-7-(3-fluorophenyl)-2-methyl-thiazolo[4,5-f]quinoline; and 7-(3-fluorophenyl)-2-methylamino- thiazolo[4,5-f]quinoline;

## REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: The prior art neither teaches nor suggests the claimed compounds, process for preparing same or pharmaceutical composition. EP 187705 teach imidazol[4,5-f]quinolines and WO 02/36562 teach quinoline compounds. Neither reference teach the thiazole- or oxazole[4,5-f]quinolines claimed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1625

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amelia A. Owens whose telephone number is 571-272-0690. The examiner can normally be reached on Monday - Friday from 8:30 - 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Amelia A. Owens Primary Examiner

Art Unit 1625